A 2023 analysis in The Lancet of GLP-1 agonist discontinuation found that patients who stopped semaglutide after 68 weeks regained approximately two-thirds of their lost weight within one year [19]
For diarrhea, maintaining hydration and considering temporary dietary adjustments may help
Currently, tirzepatide and semaglutide are available through prescription in Canada while Retatrutide remains in clinical trials with FDA approval expected in late 2026 or early 2027
Prepare for dose increase to 8mg in week 9
By mimicking the natural effects of GLP-1, these medications offer a new avenue for those struggling with obesity or overweight, providing not only improved appetite control and satiety but also better blood sugar regulation
As more affordable Semaglutide enters the Indian market, patients globally may now have more realistic long-term access options for GLP-1 therapy through compliant personal imports facilitated by MedsPartner